Drugs / FT825
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06241456 | Jan 2024 → May 2029 expected | neoplasm | Fate Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-11-12 | Fate Therapeutics | Results Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates fatetherapeutics.com ↗
Peripheral Blood from First Three Patients Demonstrates CAR T-cell Expansion with Maintenance of Activated State |
| 2024-11-09 | Fate Therapeutics | Results Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting fatetherapeutics.com ↗
As of a data cutoff date of October 25, 2024 , FT825 / ONO-8250 was well-tolerated with no DLTs and no events of any grade of CRS, ICANS, or GvHD. |
| 2023-11-08 | Fate Therapeutics | Regulatory Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates fatetherapeutics.com ↗
IND Application Cleared by FDA for FT825/ONO-8250 CAR T-cell Program for Solid Tumors |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT825 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06241456 ↗ |
| Known as | ONO-8250 | “ONO-8250” NCT06241456 ↗ |
| Modality | Cell therapy | “FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors” NCT06241456 ↗ |
| Route | Intravenous | “FT825 will be administered as an intravenous (IV) infusion” NCT06241456 ↗ |